VBI Vaccines (OTCPK:VBIV.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

VBIV.Q Stoklara Genel Bakış

Ticari aşamada bir biyofarmasötik şirketi olan VBI Vaccines Inc. immüno-onkoloji ve bulaşıcı hastalıkları tedavi etmek için aşılar geliştirmekte ve satmaktadır. Daha fazla detay

VBIV.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $14K )

Negatif hissedar öz sermayesi

Kazançlar son 5 yılda yılda 17.4% oranında azaldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 1 daha fazla risk

VBI Vaccines Inc. Rakipler

Aditxt

NasdaqCM:ADTX

US$2.8m

TRACON Pharmaceuticals

OTCPK:TCON

US$100.5k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Aridis Pharmaceuticals

OTCPK:ARDS

US$53.0

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti VBI Vaccines
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0005
52 Haftanın En Yüksek Seviyesi	US$1.35
52 Haftanın En Düşük Seviyesi	US$0.0002
Beta	2.22
11 Aylık Değişim	0%
3 Aylık Değişim	-97.37%
1 Yıllık Değişim	-99.92%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Hissedar Getirileri

	VBIV.Q	US Biotechs	US Pazar
7D	0%	2.4%	2.2%
1Y	-99.9%	16.2%	31.7%

Getiri vs. Endüstri: VBIV.Q geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: VBIV.Q geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	52.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: VBIV.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: VBIV.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 36% dan 52% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	135	Jeff Baxter	www.vbivaccines.com

Ticari aşamada bir biyofarmasötik şirketi olan VBI Vaccines Inc. immüno-onkoloji ve bulaşıcı hastalıkları tedavi etmek için aşılar geliştirmekte ve satmaktadır. Hepatit B (HBV) aşısını PreHevbrio, PreHevbri ve Sci-B-Vac markaları altında sunmaktadır. Şirket ayrıca, kronik HBV enfeksiyonunun tedavisi için protein bazlı bir immünoterapötik adayı olan VBI-2601; bir glioblastoma kanser aşısı immünoterapötik adayı olan VBI-1901; profilaktik bir sitomegalovirüs aşısı adayı olan VBI-1501 ve Zika virüsünü tedavi etmek için VBI-2501 geliştirmektedir.

VBI Vaccines Inc. Temel Bilgiler Özeti

VBI Vaccines'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VBIV.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$14.34k
Kazançlar(TTM)	-US$83.99m
Gelir(TTM)	US$9.41m

0.0x

P/S Oranı

0.0x

F/K Oranı

VBIV.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VBIV.Q gelir tablosu (TTM)
Gelir	US$9.41m
Gelir Maliyeti	US$11.67m
Brüt Kâr	-US$2.26m
Diğer Giderler	US$81.73m
Kazançlar	-US$83.99m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.93
Brüt Marj	-24.03%
Net Kâr Marjı	-892.47%
Borç/Özkaynak Oranı	-891.6%

VBIV.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VBIV.Q Stoklara Genel Bakış

Risk Analizi

VBI Vaccines Inc. Rakipler

NasdaqCM:ADTX

US$2.8m

OTCPK:TCON

US$100.5k

OTCPK:GNCA.Q

US$5.9k

OTCPK:ARDS

US$53.0

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Recent updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat